Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1051 | Moclobemide 150 mg Tablet | N06AG02000T1001XX | A* | Treatment of depressive syndrome | Initially 300 mg daily in divided doses. Gradually to increase up to 600 mg daily in divided doses depending on response. Usual range 150 - 600 mg daily. Not recommended in children | |
| 1052 | Modified Fluid Gelatin 4% Injection | B05AA06905P9901XX | B | For primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine) | ADULT 500 - 1500 ml given as IV infusion | |
| 1053 | Mometasone Furoate 0.1% Cream | D07AC13139G1001XX | A/KK | For the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | None | Apply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner. Massage gently and thoroughly until the medication disappears. |
| 1054 | Mometasone Furoate 0.1% Lotion | D07AC13-139-L60-01-xxx | A* | For the relief of the inflammatory and pruritic manifestations of the corticosteroid responsive dermatoses | None | Apply a few drops to affected skin areas including scalp sites once daily; massage gently and thoroughly until the medication disappears. |
| 1055 | Mometasone Furoate 0.1% Ointment | D07AC13-139-G50-01-XXX | A/KK | For the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | None | Apply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner. Massage gently and thoroughly until the medication disappears. |
| 1056 | Mometasone Furoate 50mcg Aqueous Nasal Spray | R01AD09-139-A41-01-XX | A* | i) Allergic rhinitis. ii) For the treatment of nasal polyps in patients 18 years of age and older. | None | ALLERGIC RHINITIS: ADULT and CHILD, 12 years and above: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved. CHILD 3 - 11 years old: 50 mcg (1 spray) to each nostril once daily. TREATMENT OF NASAL POLYPS: Two sprays (50 micrograms/spray) in each nostril twice daily (total daily dose of 400 mcg). Once symptoms are adequately controlled, dose reduction to two sprays in each nostril once daily (total daily dose 200 mcg) is recommended. |
| 1057 | Monobasic Sodium Phosphate 48%, Dibasic Sodium Phosphate 18% | A06AG01162L5001XX | A | Bowel cleansing prior to colonoscopy, radiological examination or bowel surgery | 45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. Not recommended for use in children | |
| 1058 | Montelukast Sodium 10 mg Tablet | R03DC03-520-T10-01-XX | A/KK | Chronic treatment of asthma and relief of symptoms of seasonal allergic rhinitis for children more than 15 years and adults | None | CHILD more than 15 years and ADULT: 10 mg daily at bedtime |
| 1059 | Montelukast Sodium 4mg Oral Granules | R03DC03-520-F10-01-XXX | A* | Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma | None | 12 months - 5 years: 1 packet of 4mg oral granules daily at bedtime |
| 1060 | Montelukast Sodium 5mg Tablet | R03DC03-520-T20-01-XXX | A* | Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma | None | CHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime |
| 1061 | Morphine 10 mg / 5 mL (2 mg/mL) Solution | N02AA01-183-L90-01-XXX | B | For use in management of moderate to severe pain especially that associated with neoplastic disease | None | Dosing is individualised and according to product insert / protocol |
| 1062 | Morphine Sulphate 10mg Prolonged Release Tablet | N02AA01-183-T50-01-XXX | A, A/KK | Category Prescriber A/KK: i) Prolonged relief of severe pain associated with neoplastic disease Category Prescriber A: ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed | Indication (i): Category Prescriber A/KK: To be prescribed by Family Medicine Specialists trained in pain management Indication (ii): Initiated by Pain or Palliative Specialists only | 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly. |
| 1063 | Morphine Sulphate 10mg Suppository | N02AA01-183-S20-01-XXX | A* | Relief of severe chronic pain (cancer patient) | None | 15 - 30 mg regularly every 4 hours |
| 1064 | Morphine Sulphate 10mg/ml Injection | N02AA01-183-P30-01-XXX | B | i) For moderate to severe pain especially that associated with neoplastic disease ii) As an analgesic adjunct in general anaesthesia. | None | ADULT: 5 to 20 mg every 4 hours, intravenously (IV or IM), 2.5 to 15mg should be given by slow injection. CHILD: - Adjusted according to body weight, 0.1 – 0.2 mg /kg every 4 hours. No dose should exceed 15 mg. - Analgesic Indication (i) subcutaneous, 100 mcg to 200 mcg (0.1 to 0.2 mg) per kg of body weight every four hours as needed, not to exceed 15mg per dose. Indication (ii) Intravenous, 50 to 100 mcg (0.05 mg to 0.1 mg) per kg of body weight, administered very slowly. |
| 1065 | Morphine Sulphate 20 mg Suppository | N02AA01-183-S20-02-XXX | A* | Relief of severe chronic pain (cancer patient) | None | 15 - 30 mg regularly every 4 hours |
| 1066 | Morphine Sulphate 30mg Prolonged Release Tablet | N02AA01-183-T50-02-XXX | A | i) Prolonged relief of severe pain associated with neoplastic disease ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed | Indication (ii) Initiated by Pain or Palliative Specialists only | 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain |
| 1067 | Morphine Sulphate 30mg Suppository | N02AA01-183-S20-03-XXX | A* | Relief of severe chronic pain (cancer patient) | None | 15 - 30 mg regularly every 4 hours |
| 1068 | Morphine Sulphate 5mg Immediate Release Tablet | N02AA01-183-T60-01-XXX | A* | Relief of moderate to severe pain (cancer patient) | None | 5-10 mg every four hours. The dose may be increased according to needs |
| 1069 | Morphine Sulphate 60mg Prolonged Release Tablet | N02AA01-183-T50-03-XXX | A | i) Prolonged relief of severe pain associated with neoplastic disease ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed | Indication (ii): Initiated by Pain or Palliative Specialists only | 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly. |
| 1070 | Moxifloxacin 0.5% Ophthalmic Solution | S01AX22-110-D20-01-XXX | A* | Treatment of conjunctivitis caused by susceptible organism | None | CHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3 times daily for 7 days |
| 1071 | Moxifloxacin 400 mg Injection | J01MA14110P3001XX | A* | Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae. | IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days | |
| 1072 | Moxifloxacin 400mg Tablet | J01MA14110T1001XX | A* | Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae. | IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days | |
| 1073 | Multivitamin Drops | A11BA00901D5001XX | B | For prevention and treatment of vitamin deficiencies | INFANT less than 1 year: 1 ml daily | |
| 1074 | Multivitamin Injection | A11BA00901P3001XX | B | For prevention and treatment of vitamin deficiencies | Initially 2 - 4 pairs IV 4 - 8 hourly, reducing to 1 pair IV daily. For less serious cases, 1 pair IV 1 - 2 times daily or based on individual requirements | |
| 1075 | Multivitamin Syrup | A11BA00901L9001XX | C+ | For prevention and treatment of vitamin deficiencies | CHILD 5 ml daily or based on manufacturer | |
| 1076 | Multivitamin Tablet | A11BA00901T1001XX | B | For prevention and treatment of vitamin deficiencies | 1 - 2 tablets daily or based on individual requirements | |
| 1077 | Mupirocin 2% Cream | D06AX09000G1001XX | A | Skin infection by Staphylococcus aureus (including MRSA), Staphylococcus epidermidis and beta-haemolytic streptococcus | Adults and child over 1 year, apply up to 3 times daily for up to 10 days | |
| 1078 | Mupirocin 2% Ointment | D06AX09000G5001XX | A | Bacterial skin infections by Staphylococcus and Streptococcus sp. | None | ADULT and CHILD: Apply up to three times daily for up to 10 days |
| 1079 | Mycophenolate Mofetil 250 mg Capsule | L04AA06236C1001XX | A* | i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis | i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day | |
| 1080 | Mycophenolate Mofetil 500 mg tablet | L04AA06236T1002XX | A* | i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis | i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day |